|
1
|
Goebel SU, Iwamoto M, Raffeld M, Gibril F,
Hou W, Serrano J and Jensen RT: HER-2/neu expression and gene
amplification in gastrinomas: Correlations with tumor biology,
growth and aggressiveness. J Cance Res. 62:3702–3710. 2002.
|
|
2
|
Slamon DJ, Clark GM, Wong SG, Levin WJ,
Ullrich A and McGuire WL: Human breast cancer: Correlation of
relapse and survival with amplification of the HER-2/neu oncogene.
Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen JS, Lan K and Hung MC: Strategies to
target HER2/neu overexpression for cancer therapy. Drug Resist
Updat. 6:129–136. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Feldwisch J, Tolmachev V, Lendel C, Herne
N, Sjöberg A, Larsson B, Rosik D, Lindqvist E, Fant G,
Höidén-Guthenberg I, et al: Design of an optimized scaffold for
affibody molecules. J Mol Biol. 398:232–247. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Löfblom J, Feldwisch J, Tolmachev V,
Carlsson J, Ståhl S and Frejd FY: Affibody molecules: Engineered
proteins for therapeutic, diagnostic and biotechnological
applications. FEBS Lett. 584:2670–2680. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tolmachev V and Orlova A: Influence of
labeling methods on biodistribution and imaging properties of
radiolabeled peptides for visualisation of molecular therapeutic
targets. Curr Med Chem. 17:2636–2655. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Orlova A, Feldwisch J, Abrahmsen L and
Tolmachev V: Update: Affibody molecules for molecular imaging and
therapy for cancer. Cancer Biother Radiopharm. 22:573–584. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Price EW, Zeglis BM, Cawthray JF, Ramogida
CF, Ramos N, Lewis JS, Adam MJ and Orvig C: H(4)octapa-trastuzumab:
Versatile acyclic chelate system for 111In and 177Lu imaging and
therapy. J Am Chem Soc. 135:12707–12721. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wållberg H, Grafström J, Cheng Q, Lu L,
Martinsson Ahlzén HS, Samén E, Thorell JO, Johansson K, Dunås F,
Olofsson MH, et al: HER2-positive tumors imaged within 1 hour using
a site-specifically 11C-labeled Sel-tagged affibody molecule. J
Nucl Med. 53:1446–1453. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang JM, Zhao XM, Wang SJ, Ren XC, Wang
N, Han JY and Jia LZ: Evaluation of 99mTc-peptide-ZHER2:342
Affibody® molecule for in vivo molecular imaging. Br J
Radiol. 87:201304842014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kramer-Marek G, Bernardo M, Kiesewetter
DO, Bagci U, Kuban M, Aras O, Zielinski R, Seidel J, Choyke P and
Capala J: PET of HER2-positive pulmonary metastases with
18F-ZHER2:342 affibody in a murine model of breast cancer:
Comparison with 18F-FDG. J Nucl Med. 53:939–946. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Engfeldt T, Orlova A, Tran T, Bruskin A,
Widström C, Karlström AE and Tolmachev V: Imaging of
HER2-expressing tumours using a synthetic Affibody molecule
containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl
(MAG3) sequence. Eur J Nucl Med Mol Imaging. 34:722–733. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wållberg H, Orlova A, Altai M,
Hosseinimehr SJ, Widström C, Malmberg J, Ståhl S and Tolmachev V:
Molecular design and optimization of 99mTc-labeled recombinant
affibody molecules improves their biodistribution and imaging
properties. J Nucl Med. 52:461–469. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tran T, Engfeldt T, Orlova A, Widström C,
Bruskin A, Tolmachev V and Karlström AE: In vivo evaluation of
cysteine-based chelators for attachment of 99mTc to tumor-targeting
Affibody molecules. Bioconjug Chem. 18:549–558. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee H, Zheng J, Gaddy D, Orcutt KD,
Leonard S, Geretti E, Hesterman J, Harwell C, Hoppin J, Jaffray DA,
et al: A gradient-loadable (64)Cu-chelator for quantifying tumor
deposition kinetics of nanoliposomal therapeutics by positron
emission tomography. Nanomedicine. 11:155–165. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ahlgren S, Wållberg H, Tran TA, Widström
C, Hjertman M, Abrahmsén L, Berndorff D, Dinkelborg LM, Cyr JE,
Feldwisch J, et al: Targeting of HER2-expressing tumors using a
site-specifically 99mTc-labeled recombinant Affibody molecule,
ZHER2:2395, with C-terminal engineered cysteine. J Nucl Med.
50:781–789. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Orlova A, Nilsson FY, Wikman M, Widström
C, Ståhl S, Carlsson J and Tolmachev V: Comparative in vivo
evaluation of iodine and technetium labels on anti-HER2 Affibody
for single-photon imaging of HER2 expression in tumors. J Nucl Med.
47:512–519. 2006.PubMed/NCBI
|
|
18
|
Tolmachev V, Hofström C, Malmberg J,
Ahlgren S, Hosseinimehr SJ, Sandström M, Abrahmsén L, Orlova A and
Gräslund T: HEHEHE-tagged affibody molecules may be purified by
IMAC, are conveniently labeled with
[99(m)Tc(CO)3](+), and show improved
biodistribution with reduced hepatic radioactivity accumulation.
Bioconjug Chem. 21:2013–2022. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ahlgren S, Orlova A, Rosik D, Sandström M,
Sjöberg A, Baastrup B, Widmark O, Fant G, Feldwisch J and Tolmachev
V: Evaluation of maleimide derivative of DOTA for site-specific
labeling of recombinant Affibody molecules. Bioconjug Chem.
19:235–243. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tran T, Engfeldt T, Orlova A, Sandström M,
Feldwisch J, Abrahmsén L, Wennborg A, Tolmachev V and Karlström AE:
(99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for
detection of HER2 expression in malignant tumors. Bioconjug Chem.
18:1956–1964. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ekblad T, Tran T, Orlova A, Widström C,
Feldwisch J, Abrahmsén L, Wennborg A, Karlström AE and Tolmachev V:
Development and preclinical characterization of 99mTc-labeled
Affibody molecules with reduced renal uptake. Eur J Nucl Med Mol
Imaging. 35:2245–2255. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tran TA, Ekblad T, Orlova A, Sandström M,
Feldwisch J, Wennborg A, Abrahmsén L, Tolmachev V and Eriksson
Karlström A: Effects of lysine-containing mercaptoacetyl-based
chelators on the biodistribution of 99mTc-labeled anti-HER2
Affibody molecules. Bioconjug Chem. 19:2568–2576. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Engfeldt T, Tran T, Orlova A, Widström C,
Feldwisch J, Abrahmsen L, Wennborg A, Karlström AE and Tolmachev V:
99mTc-chelator engineering to improve tumour targeting properties
of a HER2-specific Affibody molecule. Eur J Nucl Med Mol Imaging.
34:1843–1853. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tran T, Engfeldt T, Orlova A, Sandström M,
Feldwisch J, Abrahmsén L, Wennborg A, Tolmachev V and Karlström AE:
(99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for
detection of HER2-expression in malignant tumors. Bioconjug Chem.
18:1956–1964. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tran TA, Rosik D, Abrahmsén L, Sandström
M, Sjöberg A, Wållberg H, Ahlgren S, Orlova A and Tolmachev V:
Design, synthesis and biological evaluation of a HER2-specific
affibody molecule for molecular imaging. Eur J Nucl Med Mol
Imaging. 36:1864–1873. 2009. View Article : Google Scholar : PubMed/NCBI
|
